{"denoms":[{"counts":[{"groupId":"BG000","value":"231"}],"units":"Participants"}],"groups":[{"description":"Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.\n\nVAD: 3 Cycles (3rd cycle optional):\n\nVincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20\n\nHigh-Dose cyclophosphamide: Approximately 5-6 weeks after VAD 2 or 3:\n\nCytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1\n\nHemopoietic stem cell procurement: Collection target = 10 x 10\\^6 cells/kg\n\nEDAP: Approximately 5-6 weeks after high-dose cyclophosphamide","id":"BG000","title":"Study Treatment"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"211"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"26.5","upperLimit":"71.5","value":"51.6"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"91"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"140"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"231"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}